Blood biomarkers-defined subgroups show heterogeneity in post-acute COVID-19 syndrome: a rationale for precision medicine.

- Benjamin Charvet¹, Alexandre Lucas², Justine Pierquin¹, Joanna Brunel¹, Steven Fried³,
 Corinne Bernis³, Zachary S. Orban³, Millenia Jimenez³, Barbara A. Hanson³, Lavanya
 Visuabharathu³, Igor I. Koralnik³, Horvé Parron^{1*}, PhD
- 5 Visvabharathy³, Igor J. Koralnik³, Hervé Perron^{1*}, PhD.
- ⁶ ¹Geneuro-Innovation, Bioparc Laennec, 69008, Lyon, France.
- ². We-Met platform, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), plateau We-Met,
- 8 Inserm UMR1297 and Université Paul Sabatier, Toulouse, France
- ³ Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago,
 IL, USA
- 11 * Correspondence: <u>hperron@geneuro.com</u>; Hervé Perron, Geneuro-Innovation, Bioparc Laënnec,
- 12 60A Avenue Rockefeller, 69008, Lyon, France. tel : +33 437 902 997
- 13 Keywords: long COVID-19, post-COVID-19, PASC, SARS-CoV-2, Immunoglobulin isotype,
- 14 HERV-W, TLR4, cytokine, neurofilament, cognitive symptoms, brain fog.
- 15 Word count: 2741.
- 16

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has construct covers a subsection preprint on preprint on the preprint of the author/funder. No reuse allowed without permission.

17 Abstract

Acute COVID-19 can cause a post-infectious syndrome in a significant percentage of patients, with multifacted and long lasting symptoms. We hypothesized that this Post-Acute COVID syndrome (PASC) could result from various underlying causes, which may compromise the demonstration of efficacy for treatments evaluated on cohorts of heterogeneous patients.

22 To assess the feasibility of stratifying or characterizing subgroups of post-COVID-19 patients 23 consistent with different indications in a precision medicine perspective, we tested serum biomarkers 24 in a pilot cross-sectional study of patients with neuro-cognitive symptoms from the Northwestern 25 University post-COVID-19 clinic (Chicago,USA). Patient health status was evaluated with the use of 26 standardized PROMIS questionnaires and underwent validated cognitive tests with the NIH Toolbox. 27 Serum biomarkers were chosen as proteins known to be involved in the pathogenic features of a neuro-28 inflammatory disease, i.e., multiple sclerosis, with a final selection of the most discriminant ones. A 29 multi-isotypes serology against SARS-CoV-2 spike and nucleocapsid antigens was performed to allow

30 detailed analyses of the humoral immune status.

31 Despite the limited numbers of this feasibility study, results showed that clinical data could not 32 differentiate PASC patients with persisting neuro-cognitive impairment, while three major PASC 33 subgroups were identified with serum biomarkers according to the presence or absence of the HERV-34 W ENV soluble protein combined with neurofilaments light chains and, to a lesser extent, with elevated 35 levels of IL-6. SARS-CoV-2 serological results in PASC compared to healthy controls also revealed a 36 significant increase of anti-Spike and/or Nucleocapsid IgM, IgA and, unexpectedly, IgE. For IgG, a 37 significant difference was observed with Nucleocapsid only since anti-Spike IgG titers were normally 38 elevated in vaccinated controls. This multi-Ig isotypes serology may provide additional information on 39 the infectious and immunological status of individual patients and should be considered in face of a 40 potential viral persistence in some individuals.

41 Altogether the results show the feasibility of using serum biomarkers to discriminate relevant

42 subgroups or individual patients for precision medicine indications in post-COVID syndromes. This

43 pilot study paves the way to further exploring biological assays for the definition of subtypes of PASC,

44 also called long COVID, useful for the choice of relevant therapeutic strategies.

46 1 Introduction

The COVID-19 pandemic is now known to generate a post-viral syndrome with multifaceted and longlasting symptoms, variably named "Long COVID", "Post-COVID" or "Post-Acute sequelae of COVID-19 (PASC). Though the last denomination may suggest lingering post-infectious symptoms, e.g., ischemic tissue lesions following thrombotic events ¹, many symptoms appear to result from

51 ongoing pathogenic processes with possible onset of chronicity 2,3 .

52 In June 2022, the center for disease control (CDC) of the USA published that "more than 40% of adults" in the United States reported having COVID-19 in the past, and nearly one in five of those (19%) are 53 currently still having symptoms of long COVID"⁴. In September 2022, the World Health Organization 54 55 (WHO) published that "at least 17 million people in the WHO European Region experienced long COVID in the first two years of the pandemic; millions may have to live with it for years to come"⁵. 56 The data points to a secondary pandemic caused by COVID-19, in the form of a post-COVID syndrome 57 58 of unknown duration and evolution with overlapping symptoms that may result from various 59 pathogenic factors and pathways ⁶. In particular, persisting neurological and cognitive symptoms appear common and affect the quality of life on the long term 7,8 . 60

61 Diagnosing and managing such a complex syndrome is a challenge that requires understanding how to 62 identify potentially differing mechanisms underlying the overlapping symptoms observed in these 63 patients ⁹. There is a need to identify markers which will differentiate between heterogeneous long-64 COVID subgroups and guide precision medicine where possible. For this purpose, we have selected 65 biomarkers from factors already known to be involved in COVID-19 and also suspected to contribute 66 to certain aspects of long COVID or PACS. We also focused on assays suitable for routine laboratory 67 analyses on serum samples, which can be easily obtained from patients.

68 In the present pilot study on patients from a post-COVID clinic presenting with persistent symptoms 69 such as abnormal fatigue, sleep disorders and dominant neuro-cognitive symptoms, we have thus 70 studied (i) immunoglobulin isotypes of the humoral response against SARS-CoV-2 spike and 71 nucleocapsid antigens, (ii) the presence of an endogenous retroviral protein, HERV-W ENV, shown to be pathogenic for the immune and nervous systems ¹⁰⁻¹², with virus-induced expression ¹³⁻¹⁵ and 72 73 recently shown to predict disease severity when detected on lymphocytes from COVID-19 patients ¹⁶, (iii) the levels of major cytokines involved in COVID-19 inflammatory responses ¹⁷ and, because of 74 neuro-cognitive symptoms, (iv) the levels of neurofilament light chain (NfL) known to be accurate 75 76 biomarkers of neuronal impairment even when quantified in the peripheral blood ¹⁸.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has posted for the preprint of the preprint of the preprint of the author/funder. Who has posted for the preprint of the prep

78 2 Methods

79 *Participants and clinical assessment*

80 This cross-sectional study was approved by the Northwestern University Institutional Review Board

81 (STU00215866). Blood collection from patients and sample processing followed standard operating

- 82 procedures with the appropriate approval of the Ethics and Scientific Committees (num.
- 83 20210604/04/02). Written informed consent was obtained from all study participants. Importation of
- 84 the human samples received the authorization IE-2022-2309 from the French ministry. Clinical and
- 85 demographic data from PASC patients are presented in **Table 1**. PASC patient health status was
- 86 evaluated with the use of standardized PROMIS questionnaires and underwent validated cognitive
- 87 tests with the NIH Toolbox 8,19,20 .

88 Immunooassays

- 89 The detection of SARS-CoV-2 immunoglobulin isotypes (IgG, IgM, IgA and IgE) were performed on
- 90 serum by Simple Western technology (ProteinSimple/BioTechne, CA, USA) with manufacturer's
- 91 reagents according to their manual. HIS-tagged recombinant proteins of SARS-CoV-2 ((S)Spike, S1
- 92 Subunit, S2 Subunit, S1 RBD and Nucleocapsid were used to detect antibody responses to SARS-CoV-
- 93 2. The area under the curve (AUC) for the electrophoregram peak corresponding to the
- 94 immunodetection of each protein at the expected size was measured using Compass Software.
- For the detection of HERV-W ENV antigen in serum analyses were also performed with simple western-Jess, according to the conditions provided in the patent "Method for the detection of the
- 97 soluble hydrophilic oligomeric form of HERV-W envelope protein", published under ref.
- 98 WO2019201908, with previously described sample treatment (32). The specific signal was expressed
- as the signal to noise (S/N) ratio, where the noise represents the mean+2SD of the background signals
- 100 yielded by a panel of sera from healthy blood donors (EFS, Lyon-France). PASC samples were stored
- in freezers at -80°C for less than 6 months. All samples were kept frozen after their initial freezing until
- 102 use (no freeze/thaw cycle before the immunoassay).
- 103 Serum levels of NfL (# SPCKB-PS-002448) and IL-6 (# SPCKC-PS-006520) were quantified with
- 104 the fully automated immunoassay platform, Ella (ProteinSimple/Bio-techne, CA, USA). The lower
- 105 limits of quantification (LLOQ) were provided by the supplier as a threshold for normal baselines 3
- 106 pg/mL for IL-6. Age-standardized Z-scores were calculated for NfLs {Harp, 2022 #18599}. Serum
- 107 samples were run in triplicate and results in pg/mL were calculated by the instrument software
- 108 (SimplePlex Explorer, ProteinSimple/Bio-techne, USA).

109 *RT-qPCR*

- 110 Total RNA was obtained from PAXgene tubes used to collect whole blood samples and stored at -111 20°C. RNA extraction used NucleoSpin RNA Mini Kit (Macherey Nagel, 740955) according to the 112 manufacturer's protocol. 200 ng of DNase-treated RNA was reverse-transcribed into cDNA using
- iScript cDNA Synthesis Kit (Bio-Rad, 1708891) according to the manufacturer's protocol. A control
- with no-RT was used to confirm the absence of contaminating DNA. 5 ng of initial RNA in RT reaction
- 115 was used in RT-qPCR for HERV-W *ENV*, HERV-W *POL*, HERV-K *ENV*, SARS-CoV-2 N genes.
- 116 Primer sequences (5' to 3'): HERV-K ENV Forward CTGAGGCAATTGCAGGAGTT, Reverse
- 117 GCTGTCTCTTCGGAGCTGTT; HERV-W ENV Forward GTATGTCTGATGGGGGGTGGAG,
- 118 Reverse CTAGTCCTTTGTAGGGGCTAGAG; HERV-W POL Forward CCTGTACGTCCTGACTCTC,
- 119 Reverse CTTGGGCTAATGCCTGGCC; SARS-CoV-2 N Forward AAACATTCCCACCAACAG,

- 120 Reverse CACTGCTCATGGATTGTT; B2M Forward TTACTCACGTCATTCAGCAG, Reverse
- 121 GATGGATGAAACCCAGACAC. Assays used StepOnePlus instrument (Applied Biosystems) with 122 Platinum SYBR Green (Invitrogen, 11744-500). Housekeeping gene beta-2 microglobulin (*B2M*)
- normalized the results. A melting curve analysis confirmed the specificity of amplification and the lack
- of non-specific products. Quantification used the threshold cycle (Ct) comparative method: the relative
- expression was calculated as follow: $2^{-[DCt (sample) DCt (calibrator)]} = 2^{-DDCt}$, where DCt (sample) = [Ct (target
- 126 gene) Ct (housekeeping gene)] and the DCt (calibrator) was the mean of DCt of healthy controls.

127 Statistics

- 128 Statistical analyses were performed using Prism (version 9.0; GraphPad Software, La Jolla, California).
- 129 Continuous data are expressed as means \pm SD, as indicated. Normal data distribution was assessed 130 using the Shapiro-Wilk or D'Agostino & Pearson's test, assuming p-values > 0.05. Statistical
- differences were determined using Student's test (two tailed) for compared groups with normal
- distributions, with Welch's correction when SDs of samples were significantly different (F test p<0.01)
- 133 Mann-Whitney U test (two tailed) was used for compared groups without normal distribution and
- 134 Wilcoxon signed rank test (two tailed) was used for comparison when a group only or mostly
- comprised null or very low values for a given threshold. Chi-square (two tailed) test was used for
- 136 comparison of numbers in categories, replaced by Fischer's exact test when one category had zero
- 137 count. Correlation analyses were performed with Spearman test (two tailed). Statistical significance
- 138 was set at p<0.05.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has posted for the preprint of the preprint o

140 **3 Results**

A total of 41 subjects (Table 1) were evaluated in this study. Controls (Ctrl) were caregivers or volunteers from hospital (n=10) and PASC patients previously diagnosed with acute COVID-19 and presenting with neuro-cognitive symptoms, (Neuro-PASC; n=31). These included 6 posthospitalization Neuro-PASC (PNP) and 25 non-hospitalized Neuro-PASC (NNP) patients seen at Northwestern Medicine Neuro-COVID-19 clinic.

146 HERV-WENV detection

147 Following reports of HERV-W envelope RNA and protein in acute COVID-19 patients correlating with disease severity and markers of T-cell exhaustion ¹⁶, this study analyzed HERV-W ENV RNA 148 149 from whole blood and levels of soluble envelope protein (W-ENV) in serum from PASC compared to 150 Ctrl. As shown in Figure 1 A-D, about one-half (11/23 with OC-passed RNA) of PASC individuals 151 had elevated RNA levels and about one-third (10/31) had detectable W-ENV protein in serum, which 152 was significantly different from Ctrl for both analyses (Wilcoxon Signed Rank test: Ctrl W=1.00, 153 PASC W=177.00, N=7+23, p=0.0055 for whole blood RNA, and Ctrl W=10.00, PASC W=265.00, 154 N=10+31, p=0.0020 for serum protein). RT-qPCR also detects non-coding RNA and it is known that 155 HERV RNA could play physiological roles as regulatory non-coding long or small RNA ^{21,22}. Nevertheless, the presence of circulating W-ENV protein, a potent TLR4 agonist, cannot be neutral^{12,23-} 156

 $157 \quad {}^{26}.$

158 In Figure 1C PASC patients were stratified based on hospitalization status during acute SARS-CoV-2

159 infection. Positive cases for W-ENV protein represented about one fourth in the NNP subgroup (24%,

160 6/25), but a majority in the PNP subgroup (67%, 4/6). The difference of W-ENV signal to noise values

161 (S/N) between NNP and controls was significant (Wilcoxon Signed Rank test: Ctrl W=1.00, PASC

162 W=21.00, N=10+25, p=0.0313) but, probably due to the low numbers, not between PNP and Ctrl.

163 Interestingly, W-ENV positive (W-ENV+) PASC patients tended to be further from the date of

164 infection (Fig. 1D). A significant difference in the time from onset of acute COVID-19 between W-

165 ENV+ and W-ENV- patients was confirmed (Unpaired t-test with Welch's correction: t=2,346, 166 df=17,61, N=21+10, p=0.0309). Some of these cases had suffered from post-COVID symptoms for

167 two years after the acute infection, which corresponded to the beginning of the pandemic.

168

169 SARS-CoV-2 -specific antibody responses

170 To study the humoral immune response to SARS-CoV-2 infection in PASC patients, we measured the 171 levels of all immunoglobulins (IgG, IgM, IgA and IgE) versus the control group (including vaccinated

individuals) against SARS-CoV-2 nucleocapsid (N) and spike (S) antigens.

Anti-N IgG were detected in a subgroup of PASC patients but not in controls (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC W=444.0, N=10+31, p<0.0001; Fig. 1E), whereas no difference with Ctrl was observed for the anti-S IgG (Fig. 1F), which mostly indicated that Ctrl had been vaccinated with this antigen. Comparing W-ENV positive and negative PASC patients showed that anti-N IgG

177 antibodies were detected in both subgroups, each one remaining significantly different from Ctrl

- 178 (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC/W-ENV- W=193.0, N=10+21, p=0.0003; Ctrl
 179 W=0.00, PASC/W-ENV+ W=53.0, N=10+10, p=0.0039; Fig. 1G), but no difference was seen between
- 180 PASC subgroups and Ctrl for anti-spike IgG (Fig. 1H).

As shown in Figure 2, IgM against both S and N proteins were only observed in a subgroup of PASC patients with a wide range of titers. But, despite a few IgM positive PASC cases, a significant difference

- 183 was seen versus controls for anti-N IgM (Wilcoxon Signed Rank test: Ctrl W=1600, PASC W=476.0,
- N=10+31 p=0.0480; Fig. 2 A) and, with high significance, for anti-S IgM (Wilcoxon Signed Rank test:
 Ctrl W=-6.00, PASC W=183.0, N=10+29, p<0.0001; Fig. 2 B). Of note, two sera with non interpretable
- technical profiles were omitted. IgA antibodies levels were shown to be significantly elevated in PASC
- 187 versus Ctrl for both N and S antigens, but anti-N IgA better discriminated PASC versus Ctrl (Wilcoxon
- 188 Signed Rank test: anti-N IgA, Ctrl W=16.00, PASC W=476.0, N=10+31 p<0.0001; anti-S IgA, Ctrl
- 189 W=-2.00, PASC W=273.0, N=10+31 p=0.0063; Fig. 2 C-D). Surprisingly, a subgroup of PASC
- patients had elevated IgE immunoglobulins against both N and S antigens (Wilcoxon Signed Rank test:
- anti-N IgE, Ctrl W=5.00, PASC W=336.0, N=10+31 p=0.0006; anti-S IgE, Ctrl W=14.00, PASC W=456.0, N=10+21 $m \leq 0.0001$) with a large range of negitivity versus all negative centrels (Fig. 2 E
- 192 W=456.0, N=10+31 p<0.0001), with a large range of positivity versus all negative controls (Fig. 2 E-
- 193 F).

194 *IL-6 quantification*

- 195 IL-6 was suggested to play a role in acute COVID-19 severity. In PASC, only a subgroup had elevated
- 196 IL-6 (about 35%, 11/31) but, whereas most values were below the normal threshold (3pg/ml) in NNP,
- nearly all PNP (5/6) had elevated IL-6 levels in the serum with a significant difference from Ctrl (Mann
 Whitney test: U=3, N=10+6, p=0.0017;Fig. 3A). When W-ENV positive and negative PASC
- 198 Whitney test: U=3, N=10+6, p=0.0017; Fig. 3A). When W-ENV positive and negative PASC 199 subgroups were compared, the W-ENV+ patients showed significantly higher IL-6 levels (Mann
- 200 Whitney test: U=31, N=21+10, p=0.0011; Fig. 3B), consistently with the significant correlation found
- between PASC serum levels of HERV-W ENV and IL-6 (Spearman correlation test: r=0.5877, 95%
- 202 CI 0.2847 to 0.7840, pairs N=31, p=0.0005; Fig. 3C). In figure 3D, PASC were stratified according to
- both anti-N SARS-CoV-2 IgG and W-ENV serum levels. All samples from the W-ENV+ subgroup
- had elevated IL-6 levels, when compared to all other W-ENV negative sera with or without anti-N IgG
- 205 (Mann Whitney test: W-ENV+/IgG N+ Vs W-ENV-/IgG N-, U=7, N=8+9, p=0.0035; W-ENV+/IgG 206 N+ V_{2} W ENV/ (ac N+ U=10 N=8+12 r=0.0012) Fig. 2D)
- 206 N+ Vs W-ENV-/IgG N+, U=10, N=8+13, p=0.0013; Fig. 3D).

207 Neuronal impairment biomarker: Neurofilament Light chain (NfL)

- We measured the levels of serum NfL in PASC with cognitive impairment, since shown to be an accurate peripheral biomarker of neuronal degeneration or injury within the central nervous system²⁷ (Figure 3E-G). Results were normalized with Z-score according to the age of the patients or control
- 211 individuals, as already defined 28 .
- 212 No significant difference was found between the distributions of NfL serum levels in PNP versus NNP,
- 213 nor Vs Ctrl (Fig. 3 E). Nonetheless, when stratified with W-ENV, all (100%, 10/10) W-ENV+ patients
- had elevated levels of serum NfL while only 62% (13 out of 21) of W-ENV-negative sera had a NFL
- 215 Z-scores above 0 (Fisher exact test = 0.0317 p < 0.05, $\alpha = 1$, N=31; Fig. 3 F). Moreover, Z-scores were
- 216 all above zero in the subgroup with both W-ENV and anti-N IgG positivity which was significantly
- 217 different from the anti-N IgG+ and W-ENV- subgroup (Unpaired t test with Welch's correction:
- 218 t=2,688, df=17,61, N=22, p= 0,0152; Fig. 3G),.

219 Biomarker-defined subgroups

- 220 Figure 3H represents clusters of all PASC patients studied for the above-mentioned serum biomarkers.
- 221 Within the W-ENV+ subgroup the majority (7/10) of PASC were positive altogether for NfL, IL-6 and
- IgG anti N-SARS-CoV-2 but only one (1/21) in the W-ENV negative subgroup (Chi-square
- statistic=17.890, p=0.00002, $\alpha=1$, N=31 tested on all parameters). All W-ENV+ Neuro-PASC had
- positive serum levels of NfL (10/10). Moreover, within the W-ENV + subgroup, the NfL+ cluster included all U 6^+ or Ic anti N+ core and therefore acting ided with W ENV accidition in N-RASC
- included all IL-6+ or Ig anti-N+ sera and therefore coincided with W-ENV positivity in Neuro-PASC
- patients, i.e., defined the same subgroup when combined with W-ENV positivity. Matching with acute
 COVID effective hospitalization also, all HERV-W ENV+ patients from the PNP subgroup were
- 228 positive for the three other biomarkers (NfL, IL-6 and IgG anti-N; data not shown).

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has posted for the preprint of the preprint o

- 229 Within the W-ENV- subgroup, a single case was positive for NfL, IL-6 and IgG anti-N altogether. As
- 230 found to be the core parameters in the W-ENV+ subgroup, this may question the sensitivity of the
- 231 present test for HERV-W ENV soluble antigen detection in serum. The patterns for single or double
- 232 positivity appeared to be variable while only NfLs positive levels were dominant, thereby suggesting
- 233 relationship with the neuro-cognitive impairment in this cohort. However, a cluster was clearly
- identified to be negative for all these biomarkers, beyond negativity for W-ENV as well. This "all
- negative" cluster is consistent with very different pathogenic factors involved in their post-COVID
- symptomatology.
- 237 Of note, though all W-ENV+ patients had positive Z-scores for NfL, taken alone this biomarker
- 238 revealed dominant in all Neuro-PASC cases, W-ENV+ and W-ENV- (Figure 3F). Negative Z-scores
- 239 were found in few cases positive for IL-6 only or for IgG anti-N only but, most interestingly, within
- 240 the isolated cluster negative for all tested biomarkers (figure 3H).
- 241 SARS-CoV-2 serology showed significant differences with controls for anti-N IgG (Figure 1E) and
- for anti-N and/or anti-S IgM, IgA or IgE (Figures 2A-F). But, even in combination with other biomarkers, it did not provide a clear-cut stratification when considered without the other studied
- biomarkers.
- Therefore, Neuro-PASC subgroups could be defined as (i) W-ENV+ and NfL+, (ii) W-ENV- and (NfL+ or IL-6+ or IgG anti-N+) and (iii) negative for all the tested parameters. In addition, possible
- indication may be also provided on SARS-CoV-2 persistence by IgM, on the route of infection in
- 248 extrapulmonary cases²⁹ or on the site of persistence by IgA and, particularly, on potentially associated
- 249 immunoallergic symptoms by IgE.
- 250 Finally, using data from the PROMIS scale³⁰ and other clinical data showed no significant difference
- in the distribution of results between the subgroups consistently defined by the different biomarkers as
- exemplified with HERV-W ENV and anti-N-SARS-CoV-2 IgG in Figure 4.
- 253

254 Conclusion

255 The present results, despite the limited number of patients, consistently identified three major Neuro-256 PASC subgroups with significant differences stratified according to the presence or absence of the 257 HERV-W ENV protein combined with positive Z-score for NfLs in serum. SARS-CoV-2 serology 258 with all Ig isotypes should also provide useful indications on the infectious status, with possible viral 259 persistence or a possible immunoallergic specific phenotype linked to elevated anti-spike or 260 Nucleocapsid IgE. Since clinical data could not differentiate consistent subgroups of patients, unlike 261 biological parameters, the biomarker-defined subgroups or clusters may be considered for differing 262 therapeutic indications in post-COVID treatment. This should be a prerequisite for clinical trials to 263 avoid mixing patients with and without the pathogenic target of a given drug, which may generate non-264 significant results versus placebo, despite possibly responding cases. Thus, the presented biomarker 265 and serology-based stratification should pave the way to precision medicine in post-acute COVID 266 sequalae or syndromes. Based on the present proof of concept and on that of other studies, a diagnostic-267 based therapy with an anti-HERV-W ENV neutralizing antibody (Temelimab) is being evaluated in a 268 clinical trial with PASC patients positive for the HERV-W ENV protein in serum (NCT).

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has construct covers a subsection preprint on preprint on preprint on the author/funder. No reuse allowed without permission.

269 Figure Legends

270

271 Figure 1. HERV-W ENV and Anti-Nucleocapsid IgG antibody are significantly detected in PASC. A, HERV-W 272 ENV mRNA detection in PBMCs based on change fold of $2^{-\Delta\Delta CT}$ compared to the mean of control groups; blue dots: controls 273 group; red dots: PASC group. Here, a lower number of samples was analyzed, since 8 PASC and 3 controls yielded too 274 low RNA concentration or did not pass QC (RIN<8). B, HERV-W ENV soluble oligomeric protein detection in serum of 275 patients, results are expressed on total signal normalized with the mean of background noise measured on control cohort; 276 blue dots : controls group; red dots : PASC group. C, post-hospitalized subgroup (PNP) is extracted from the PASC group 277 and compared to PASC subgroup not hospitalized during acute COVID-19 (NNP); blue dots: controls group; red dots: NNP 278 subgroup; dark red dots: PNP sub group. D, Comparison of the time from onset between HERV-W ENV- and HERV-W 279 ENV+ PASC subgroups; grey dots: PASC HERV-W ENV- subgroup; orange dots: PASC HERV-W ENV+ subgroup. E, 280 IgG anti-SARS-CoV-2 Nucleocapsid; F, IgG anti-SARS-CoV-2 Spike. Comparison between PASC HERV-W ENV- and 281 PASC HERV-W ENV+ subgroups for IgG anti-Nucleocapsid (G), and anti-Spike (H). The value on the Y-axis (U) 282 represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the immunodetected Ig 283 isotype from tested sera against each antigen.

Figure 2. PASC serological IgM, IgA and IgE. A, IgM anti-SARS-CoV-2 Nucleocapsid; B, IgM anti-SARS-CoV-2 Spike IgM anti-S and N of two PASC patients with inconsistent results and diverging triplicate values were not be interpretable and therefore not taken into account in this analysis.; C, IgA anti-SARS-CoV-2 Nucleocapsid; D, IgA anti-SARS-CoV-2 Spike; E, IgE anti-SARS-CoV-2 Nucleocapsid and F, IgE anti-SARS-CoV-2 Spike. The value on Y axis (U) represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the immunodetected Ig isotype from tested sera against each antigen.

290 Figure 3. Interleukine-6 (IL-6), neurofilament light chain (NfL) biomarkers and combination with HERV-W ENV 291 or anti-nucleocapsid IgG (IgG anti-N) status stratifying PASC patients. A, IL-6 dosages for controls (bleu dots), NNP 292 (red dots) and PNP (dark red dots). B. IL-6 dosage comparisons between HERV-W ENV- and HERV-W ENV+ subgroups 293 in PASC cohort. C, correlation between IL-6 and HERV-W ENV levels in serum. D, IL-6 levels in PASC patients stratified 294 by: HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) and HERV-W ENV+ / IgG anti-295 N+ (red dots). E, NfL Z-Scores of controls (blue dots), NNP (red dots) and PNP (dark red dots). NfL Z-scores comparisons 296 between HERV-W ENV- and HERV-W ENV+ subgroups in PASC cohort. G, NfL levels in different PASC subgroups: 297 HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) and HERV-W ENV+ / IgG anti-N+ 298 (red dots). H, Graphical presentation of patients' clusters defined by the selected serum biomarkers, within HERV-W ENV 299 negative and HERV-W ENV positive subgroups. The sera positive for each biomarker are represented by dots in the colored 300 circles; those negative for all parameters are in the grey oval.

Figure 4. Comparison of clinical data between groups based on HERV-W ENV and serology profiles. Three groups
 from the PASC cohort are represented based on main biomarkers results: HERV-W ENV+ /Igs anti-SARS-CoV-2
 Nucleocapsid (Ig anti-N) +; HERV-W ENV- /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N) + and HERV-W ENV- /Igs
 anti-SARS-CoV-2 Nucleocapsid (Ig anti-N). Several parameters were studied: A, Processing speed; B, Attention; C,
 Executive function; D, Working Memory; E, Cognitive function; F, Fatigue; G, Anxiety; H, Depression and I, Recovery
 compared to the baseline.

308 **Conflict of Interest**

- 309 HP, BC, JB and BC receive compensation from Geneuro-Innovation for their work. The other authors
- 310 declare that the research was conducted in the absence of any commercial or financial relationships
- 311 *that could be construed as a potential conflict of interest.*
- 312

313 Author Contributions

- 314 IK : conceptualization of the study, evaluating all patients in the Neuro-COVID-19 clinic,
- 315 supervising patients sample collection, manuscript editing and review
- NW collaborators: Zack and Millenia: organized sample and data collection from all Neuro-PASC
 and control patients at Northwestern University, manuscript review
- 318 Barbara and Lavanya: Conceptualization of the study, assisted in sample and data collection from all
- 319 Neuro-PASC and control patients at Northwestern University, editing and reviewing the manuscript
- 320 HP: conceptualization, supervision, formal analysis, investigation, data curation, writing and 321 manuscript review.
- AL, CB, SF: HERV-W-ENV detection, NfL, cytokines HERV-W-ENV detection, NfL, cytokines,
 serological analyses.
- 324 B.C.: methodology, management interpretation of analyses and manuscript review.
- 325 J.P: Serological and antigenemia analyses; graphs, figures drawing and manuscript review.
- 326 J.B.: PCR, serological and antigenemia analyses; graphs, figures drawing and manuscript review.
- H.P. and E.O.: conceptualization, funding acquisition, supervision, formal analysis, investigation, data
 curation, writing original draft and manuscript review.
- 329 All authors contributed to the article and approved the submitted version.
- 330
- 331

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has construct covers a subsection preprint on preprint on preprint on the author/funder. No reuse allowed without permission.

332 **References**

333

Hamouda D, Jillella DV, Bhatt N, Koneru S, Frankel MR, Nogueira RG. Intraluminal carotid
 thrombosis and acute ischemic stroke associated with COVID-19. *J Neurol*. Dec 2021;268(12):4443 4447. doi:10.1007/s00415-021-10562-1

Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathyassociated morbidity in Covid-19 patients. *Ann Clin Transl Neurol*. Nov 2020;7(11):2221-2230.
doi:10.1002/acn3.51210

Nehme M, Braillard O, Chappuis F, CoviCare Study T, Guessous I. The chronification of post COVID condition associated with neurocognitive symptoms, functional impairment and increased
 healthcare utilization. *Sci Rep.* Aug 25 2022;12(1):14505. doi:10.1038/s41598-022-18673-z

343 4. CDC. Prevalence of long COVID in the USA. 2022.

344 5. WHO. Long COVID in the WHO European Region. 2022.

Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al. Estimated Global
Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters
Following Symptomatic COVID-19 in 2020 and 2021. *JAMA*. Oct 25 2022;328(16):1604-1615.
doi:10.1001/jama.2022.18931

Ali ST, Kang AK, Patel TR, et al. Evolution of neurologic symptoms in non-hospitalized
COVID-19 "long haulers". *Ann Clin Transl Neurol*. Jul 2022;9(7):950-961. doi:10.1002/acn3.51570

8. Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive
dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol.* May
2021;8(5):1073-1085. doi:10.1002/acn3.51350

9. O'Hare AM, Vig EK, Iwashyna TJ, et al. Complexity and Challenges of the Clinical Diagnosis
and Management of Long COVID. *JAMA Netw Open*. Nov 1 2022;5(11):e2240332.
doi:10.1001/jamanetworkopen.2022.40332

Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein
of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and
promotes Th1-like responses. *J Immunol*. Jun 15 2006;176(12):7636-44.

Firouzi R, Rolland A, Michel M, et al. Multiple sclerosis-associated retrovirus particles cause
T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. *J Neurovirol*.
Feb 2003;9(1):79-93. doi:10.1080/13550280390173328

363 MN2N2T34QVXHRWNY [pii]

Kremer D, Gruchot J, Weyers V, et al. pHERV-W envelope protein fuels microglial celldependent damage of myelinated axons in multiple sclerosis. *Proc Natl Acad Sci U S A*. Jul 23
2019;116(30):15216-15225. doi:10.1073/pnas.1901283116


Ruprecht K, Obojes K, Wengel V, et al. Regulation of human endogenous retrovirus W protein
expression by herpes simplex virus type 1: implications for multiple sclerosis. *J Neurovirol*. Feb
2006;12(1):65-71. doi:T6G5G8M106986441 [pii]

370 10.1080/13550280600614973

- 14. Charvet B, Reynaud JM, Gourru-Lesimple G, Perron H, Marche PN, Horvat B. Induction of
 Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus6A and CD46 Receptor Engagement. *Front Immunol.* 2018;9:2803. doi:10.3389/fimmu.2018.02803
- 15. Li F, Nellaker C, Sabunciyan S, et al. Transcriptional derepression of the ERVWE1 locus
- following influenza A virus infection. *J Virol*. Apr 2014;88(8):4328-37. doi:10.1128/JVI.03628-13
- Balestrieri E, Minutolo A, Petrone V, et al. Evidence of the pathogenic HERV-W envelope
 expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.
 EBioMedicine. Apr 2021;66:103341. doi:10.1016/j.ebiom.2021.103341
- 17. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV2. *Nat Immunol*. Feb 2022;23(2):165-176. doi:10.1038/s41590-021-01091-0
- 18. Fisse AL, Pitarokoili K, Leppert D, et al. Serum neurofilament light chain as outcome marker
 for intensive care unit patients. *J Neurol*. Apr 2021;268(4):1323-1329. doi:10.1007/s00415-02010277-9
- Lai JS, Wagner LI, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: two
 sides of one coin? *Psychooncology*. Oct 2014;23(10):1133-41. doi:10.1002/pon.3522
- 20. Lai JS, Cella D, Choi S, et al. How item banks and their application can influence measurement
 practice in rehabilitation medicine: a PROMIS fatigue item bank example. *Arch Phys Med Rehabil*.
 Oct 2011;92(10 Suppl):S20-7. doi:10.1016/j.apmr.2010.08.033
- Wilson KD, Ameen M, Guo H, et al. Endogenous Retrovirus-Derived lncRNA BANCR
 Promotes Cardiomyocyte Migration in Humans and Non-human Primates. *Dev Cell*. Sep 28
 2020;54(6):694-709 e9. doi:10.1016/j.devcel.2020.07.006
- 392 Chishima T, Iwakiri J, Hamada M. Identification of Transposable Elements Contributing to 22. 393 **Tissue-Specific** Expression of Long Non-Coding RNAs. Genes (Basel). Jan 9 394 2018;9(1)doi:10.3390/genes9010023
- Johansson EM, Bouchet D, Tamouza R, et al. Human endogenous retroviral protein triggers
 deficit in glutamate synapse maturation and behaviors associated with psychosis. *Science Advances*.
 2020;6(29):eabc0708. doi:10.1126/sciadv.abc0708
- 398 24. Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R. MSRV envelope protein is a 399 potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in 400 multiple sclerosis treatment. JNeuroimmunol. Feb 15 2016;291:29-38. 401 doi:10.1016/j.jneuroim.2015.12.006
- 25. Duperray A, Barbe D, Raguenez G, et al. Inflammatory response of endothelial cells to a human
 endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. *Int Immunol*. Nov
 2015;27(11):545-53. doi:10.1093/intimm/dxv025
- 405 26. Kremer D, Schichel T, Forster M, et al. Human endogenous retrovirus type W envelope protein
 406 inhibits oligodendroglial precursor cell differentiation. *Ann Neurol.* Nov 2013;74(5):721-32.
 407 doi:10.1002/ana.23970
- 408 27. Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with
 409 10-year MRI outcomes in multiple sclerosis. *Ann Clin Transl Neurol*. Dec 2018;5(12):1478-1491.
 410 doi:10.1002/acn3.638
- 411 28. Harp C, Thanei GA, Jia X, et al. Development of an age-adjusted model for blood 412 neurofilament light chain. *Ann Clin Transl Neurol*. Apr 2022;9(4):444-453. doi:10.1002/acn3.51524

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has cost the coverage of the preprint of the


- 413 29. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat* 414 *Med.* Jul 2020;26(7):1017-1032. doi:10.1038/s41591-020-0968-3
- 415 30. Vartanian K, Fish D, Gronowski B, Kenton N, Robicsek A. Patient-Reported Outcomes for
- 416 Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough Cases.
- 417 Patient. Nov 7 2022:1-12. doi:10.1007/s40271-022-00605-8



Α

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Is anti-SARS-Covi-2 - Spike

В







Figure 4 medRxiv preprint doi: https



PASC	PASC	PASC				_	PASC			-	-		PASC	-	1.75		-		1000						-	- 1	-	-	-	<u> </u>			-	2.01	90	20	111	-	12.5	Group		TABLE 1
Male	Female	Male	Male	Hine Hine			ore T w	prin	nt c	t ce	Att	os: ed	/de	pe		evi	ew	1/2 is	02: the	0 au	tho	2 r/fu	size und	80 er,	<mark>)3</mark> ; wh	this	- ve	arsi	on	pos d m	ted	I Ma Rxi	arch v a	13 lice	nse)23 to	dis	ne c plav	opy	right holder fo preprint in pe	r this	preprint uity.
8.8	50-69	55-60	65-70	08-55	20-25	5	69-55	25-30	30-35	10-15	25-30	15-20	25-30	69-55	50-89	35-40	35-40	Rel B	9hi	Set.	-Sec	RAG FAG	8-8	10.8	19 B	se B	e allo	Se of the second	10-5-	vith B	9 M	<u>e</u> e	in the second se	ssic &	的. 日		5 6 6	55-60	25-30	Age	aphilos	
377	482	416	373		H	6	358	346	MS	203	274	36	ä	305	EM	260	242	#	252	221	ZES	275 2150	362	115	200	SET	900	Unknown	100	787	6	324	806	11	8	110	12	: #	316	Days from list		
349	242	38			320	189	335	57	17	162	243	12	319	8	122		207	11	162	199	214		241	94	199	214	120	Unknown	171	258	39	ä	281	195	5 6		11	334	294	Days from 2nd vaccine		
ž	-	156			124	88	1			75			97				EZ		32							26		40		1.1	_	106	-					88	-	Days from C 3rd		
2	Positive	Ra	Positive	Negative	Positive	Positive	Positive	Positive	-	Positive	Positive		na	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Posicive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Vegative	Negative	Negative	Negative	Manager Ma	WEBSINE	Negative	Negative	SARS- Colv-2. RT- PCR results	Clinical data	
R	2	R	na -	B	R	2	8	2	Positive	B	R	Positive	2	na	R	B	R.	R.	2	R	R	R	B	D3	R	2	R	R	R	2										SARS- CoV-2 Antigen test		
772	DEL	慶	516	524	311	1	138	112	*	176	444	711	316	61	360	815	377	202	626	371	88	×.	BBS	SI	38	805	372	43	35	EEE										Days from acute onset		
18	Yes	Yes	Yes	No	М	8	8	8	6	No	No	10	No	No	No	No	No	No	Yes	10	No	No	No	10	No	10	10	8	Yes	No				Ŭ,		2	F 8	6	6	hospita- lized for COVID- 199		
	19	σ	00													0			5		_		- 52					0724	09											Days hospita-		
18	Yes	R	Yes	6	5	6	6	6	No	No	6	6	6	10	16	No	No	No	No	6	6	6	Yes	No	6	6	6	6	Yes	Yes						N	FB	6	8	nia?		
8	YB	Yes	No	No	No	8	6	8	М	No	No	10	No	No	16	No	No	No	(B	10	6	No	No	8	8	10	6	No	NR.	No							F 8	6	6	hy poxia?		
D.a	10x	No	m.a U														51.11		No									-	N/K										100	innula-e		
đ	ie:	8	Interiorie																8										les											encepha-		
(R	Yes	1es	18		2.4					8		Yes		Yes	2	0	2.33	Yes		Yes	2	0.2	Yes	1					10	Yes								0	2.2	Fog Fo		
No	(B)	0R	YB.	Y CR	(R	08	0R	YOR .	ŐR	(B	(R			No			YB	18		100 ION	10R		100				-		(R	Ý.	_		-	_	_		-	+	-	Fatigue A	M	
8	Yes	8	Yes	Yes	8	Ver 1	le l	6	6	Yes	8	Yes	8	Yes	Yes	No	No	Yes	Ves	Yes	Yes	Yes	Yes	8	Yes	8	Yes	8	Yes	Yes							+	-	201	Anosmia D	Neurobgical symptoms	
No	No	No	N.	100	No	09	0Â	No	No	No	No	No	No	Ŕ	18	NB.	No	10	NR.	Ŕ	Ŕ	Ŕ	19	No	0Â	No	1 R	No	0X	1 Ex										Dygensia	mptoms	
(R	YR	Ye	No	6	6	NR I	8	Yß	6	YB	10	Y _B	Yes	Yes	YB	No	No	No	Yes	YR	YB	6	No	YB	YB	Y _R	Y _R	6	Yes	YR										Depression / Anxiety		
8	ER.	8	R		Œ	8	8	R.	99		8	ũ	æ	4	6	ų.	a.	8	8	N.	IR	8	8	8	æ	ы	Œ	IR	I	8	nz	20	8.0	ы	20		116	20	10	% recovered /baseline		
25		30	13	15	15	69	0	25	61	32	10	R	n	-02	55	3E	51	25	<u>91</u>	06	8	a.	25	35	6E	50	22	10	П	48	2.0	Native	1.2	2.0	2,0	1.1		2.4	2.2	22	<u> </u>	
12	m	łał	8		5	12	85	64	10	5	5	24	85	. 0	Ē	8	Œ	85	E	5	12	*	Œ	*	R	85	6	4	E.	*	11	Negative	z	2	2 1	114		z	z	1 2	Taolbox	
55	5	154	53	12	12	76	59	11	13	8	12	la l	12	49	- 44	22	H	45	31	40	55	16	11	Ţξ	-63	66	11	41	UL I	41	-	-		n.a			1		р. 8	Executiv a e Function T-score	S.	
10	157	45	60	45	10	12	5	3E	50	01	£5	-	45	8	60	45	05	36	6E	45	12	11	42	54	15	8	19	43	θί.	35	-+	*		n				12	n			
	11.4	19,1	92	13	IJ	15	38,1	40	40	ft	ы	e	33	10	IJ	41	0E	15	778	0E	45	255	40	19	10	Эř	34	15	11	н	-		2.0	11	11	1.0		1,2	n.t	Cognitive Function T- score		
Noderate	8	Moderate	Normal	Normal	Noderate	Mild	Nodaste	RM	RN	Nodrziz	Nodesta	NR	Noderste	Nodesta	Moderate	REN	Nodesta	Normal	Nodezte	Noderate	Normal	Nodrziz	PEN	Śmaz	Noderate	Nodezte	Nedezte	Nodezia	Nodesta	Nodeste	z	Negative	R.	2	a 1	5 G		E	г	Cognitive Function Category		
55	2	£	22	55	-	+	+	88	15	-	55		55	54	-	-	66		858	35	-		g	-		-	-	12	- 26	15	-	-	r;	2	e 1			1	2	and the second sec		
Moderate	n.5	Noderate	RM	Mild	Severe	Mederate	Nie	Moderate	RSN	Severe	MM	Mile	Moderate	Moderate	RSN	Noterzie	Mederate	Noderate	Moderate	Sentre	Normal	Noderate	Moderate	Severe	Nederate	Severe	Moderate	MIN	Severe	RN	-	-	8.0	1.1	5.0		1.1.1	8.8	1.2	e Fatigue Gategony		
24	-	55,4	45	45	-	-	-	-	85		8	-	8			5		55	Tig	695			15	-	-	-		5	12	12	-	-	1.1	na -				7.2	p.e		9	
Moderate	e	Moderate	Normal	Normal	Modera	Noderate	Normal	Mederate	PBN	PBN	Moderate	PBN	Mid	Moderate	Mid	Moderate	Norma	PBN	States	Moderate	Modera	Moderate	PBN	Sare	Modera	Nederate	Moderate	Normal	Mad	Moderate	-	-	z	2	e 1			E	R	Amiety Amiety T-Score Category	PROMIS	
		SIS a	1 1			+	45				10			12 SI					£13	LIS. at			17								-			1.1				1.1	n.a			
Moderate	P	RN	Normal	Normal	Nonul	Moderate	Normal	Normal	NR	RN	RN	Norral	Normal	RN	Nerral	Moderate	Nonul	Normal	Moderate	Moderate	Normal	Normal	Nonul	Servere	Norral	Moderate	PEN	North	Normal	Normal	+		7.0	24	2 1				2	Depresion Depression T-Score Gategory	3	
	n	¥8	5					LD LD	HS.	B	in			B			5		e 61,4				8			-	-	-		80	+	-	1.1	112	10			N	12	1 00		
Noma	ra	MRd	PBN .	Norta	Mad	Nodes	Noma	Noma	PBN	Nodezi	Noma	Noma	Norral	Nodesta	Modera	Nodezta	Nona	Nodeste	Nodeste	Noderate	Nodez	Nodazi	PBN	Med	Wodes:	-	Noderate	-	- 22	Nodeste	-	-	2	2	2 1			e z	R	0	3	
					in	"				H	1		2	展	R.	H.		祥	應	Ħ	Æ	H.	10	1	展	R.	R	111	Eu	権		1			1				100	17 100 100	0-0	1